The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The significance of CR as an endpoint in frail patients with multiple myeloma
Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the significance of complete response (CR) as an endpoint for frail patients with multiple myeloma. She notes that while high measurable residual disease (MRD) negativity and complete response (CR) rates are seen in some studies, progression-free survival (PFS) curves may not fully reflect the depth of response due to high discontinuation rates. She emphasizes the importance of balancing efficacy and toxicity, as each patient has a threshold for drug density that can be administered. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
